Highland announces positive data for new ADHD drug

Privately-held Canadian firm Highland Therapeutics has announced positive clinical data from the first of two phase III pivotal trials of a next-generation methylphenidate called Benjorna under development as the first attention deficit hyperactivity disorder (ADHD) formulation designed for dosing before bedtime.

Highland said Benjorna may represent a fundamental change in the way physicians will treat ADHD, targeting onset of action from the active ingredient upon awakening, throughout the school day and into the evening homework period.

The drug uses Delexis, a novel oral once daily drug delivery platform with a delayed release coating designed to remain intact for six to eight hours.